Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: GE Junction Cancer Clear all
Completed Phase 2 Interventional Results available

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

NCT00319735
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Radiation Therapy, Surgery, Tissue Sample
Procedure
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Galesburg, Illinois • Indianapolis, Indiana • Terre Haute, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

NCT00165464
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, GE Junction Cancer
Interventions
Taxotere, Cisplatin, Irinotecan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

NCT03279237
View directory record Official record
Conditions
GastroEsophageal Cancer
Interventions
Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, Paclitaxel, Radiation Therapy, Carboplatin
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

NCT02317991
View directory record Official record
Conditions
Gastroesophageal Cancer
Interventions
nab-paclitaxel, ramucirumab
Drug · Biological
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
11
States / cities
Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 21, 2026, 9:49 AM EDT
Withdrawn No phase listed Observational

Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma

NCT05067842
View directory record Official record
Conditions
Adenocarcinoma Esophagus
Interventions
Circulating tumor DNA(ctDNA) level measurement
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 21, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional Results available

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

NCT01774851
View directory record Official record
Conditions
HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
Interventions
MM-111, Paclitaxel, Trastuzumab
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

NCT00086996
View directory record Official record
Conditions
Esophageal Cancer
Interventions
fluorouracil, oxaliplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
143
States / cities
Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 92 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Jul 21, 2026, 9:49 AM EDT
Recruiting No phase listed Observational

Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

NCT01048281
View directory record Official record
Conditions
Stomach Cancer, Gastro-Esophageal(GE) Junction Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST)
Interventions
Blood draw, Tissue tumor biopsy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2099
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 21, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional

Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

NCT00103103
View directory record Official record
Conditions
Gastric Cancer
Interventions
bortezomib, fluorouracil, leucovorin calcium
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Jul 21, 2026, 9:49 AM EDT
Terminated Phase 1Phase 2 Interventional

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00561197
View directory record Official record
Conditions
Locally Advanced Esophageal or GE Junction Cancer
Interventions
AT-101
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jul 21, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

NCT00256269
View directory record Official record
Conditions
Esophageal Cancer, Gastroesophageal Cancer
Interventions
Oxaliplatin, Irinotecan
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

NCT00526669
View directory record Official record
Conditions
Neoplasms, Gastrointestinal Tract
Interventions
Lapatinib and Capecitabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
8
States / cities
Loma Linda, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 21, 2026, 9:49 AM EDT
Withdrawn No phase listed Observational

Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers

NCT01031056
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Gynecologic Cancers, Gynecologic Cancers Cervical Cancer, Gastric (Stomach) Cancer, Gastro-Esophageal(GE) Junction Cancer, Gastrointenstinal Stromal Tumor (GIST), Colon/Rectal Cancer, Colon/Rectal Cancer Colon Cancer, Colon/Rectal Cancer Rectal Cancer, Colon/Rectal Cancer Anal Cancer, Anal Cancer, Hepatobiliary Cancers, Hepatobiliary Cancers Liver, Pancreatic Cancer
Interventions
Blood Draw, Frozen Tumor Specimens
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2099
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Results available

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

NCT01183559
View directory record Official record
Conditions
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
Interventions
Vandetanib, 5 Fluorouracil (FU), Carboplatin, Paclitaxel, External Beam Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 3 Interventional Results available

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

NCT00680901
View directory record Official record
Conditions
Neoplasms, Gastrointestinal Tract
Interventions
Lapatinib, Placebo, Capecitabine, Oxaliplatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
10
States / cities
Alhambra, California • Fullerton, California • La Verne, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Early Phase 1 Interventional

Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma

NCT00215514
View directory record Official record
Conditions
Stomach Cancer, Gastric Cancer, Gastro-esophageal Junction Cancer
Interventions
Epirubicin, Cisplatin, 5-Fluorouracil (5-FU), Radiation
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Jul 21, 2026, 9:49 AM EDT
Withdrawn Phase 2 Interventional

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

NCT00620607
View directory record Official record
Conditions
Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer, Metastatic or Local Advanced GE Junction Cancer
Interventions
huC242-DM4
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Jul 21, 2026, 9:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT01142388
View directory record Official record
Conditions
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage IV Esophageal Cancer AJCC v7
Interventions
Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
232
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 173 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

NCT01611857
View directory record Official record
Conditions
Malignant Solid Tumour, Gastroesophageal Cancer
Interventions
Tivantinib, FOLFOX
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
New Haven, Connecticut • Fort Myers, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

NCT00517829
View directory record Official record
Conditions
Gastric Cancer Adenocarcinoma Metastatic
Interventions
Docetaxel, cetuximab, oxaliplatin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional

A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer

NCT00952497
View directory record Official record
Conditions
Gastric Cancer
Interventions
Cisplatin, Capecitabine, Telatinib
Drug
Lead sponsor
ACT Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
San Francisco, California • Macon, Georgia • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

NCT00165191
View directory record Official record
Conditions
Adenocarcinoma of Stomach, Adenocarcinoma of GE Junction, Adenocarcinoma of Esophagus
Interventions
Doxorubicin, Cisplatin, 5-fluorouracil
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

NCT03165994
View directory record Official record
Conditions
Esophageal Cancer, GastroEsophageal Cancer
Interventions
APX005M, Radiation Therapy, Paclitaxel, Carboplatin, Surgical resection of tumor
Drug · Radiation · Procedure
Lead sponsor
Apexigen America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Jul 21, 2026, 9:49 AM EDT
Completed Phase 2 Interventional

Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

NCT00259987
View directory record Official record
Conditions
Adenocarcinoma
Interventions
Lapatinib (GW572016) oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Jul 21, 2026, 9:49 AM EDT